莱美药业(300006) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥181,120,476.19, a decrease of 20.09% compared to ¥226,654,528.42 in the same period last year[3] - The net loss attributable to shareholders was ¥4,575,299.38, compared to a net loss of ¥3,634,060.91 in Q1 2023[3] - The net profit for the first quarter of 2024 was CNY 31,378, compared to a net loss of CNY 7,606,050.33 in the same period last year[22] - Operating profit for the first quarter was CNY 1,807,967.80, a significant improvement from a loss of CNY 3,235,229.19 in the previous year[22] - The total comprehensive income attributable to the parent company was CNY -4,575,299.38, compared to CNY -3,634,060.91 in the previous year[22] - The basic and diluted earnings per share were both reported at CNY -0.0043, compared to CNY -0.0034 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities increased significantly by 725.99%, reaching ¥79,222,721.89, up from ¥9,591,286.80 in the previous year[3] - The net cash flow from financing activities increased by 191.44% to ¥28,273,285.36, compared to ¥9,701,154.19 in Q1 2023[10] - Cash flow from operating activities increased to CNY 79,222,721.89, up from CNY 9,591,286.80 in the prior year[24] - The net cash flow from financing activities was CNY 28,273,285.36, compared to CNY 9,701,154.19 in the same period last year, indicating a strong improvement[25] Expenses - The company reported a 30.19% reduction in selling expenses, amounting to ¥87,901,058.33, due to decreased revenue[9] - Research and development expenses decreased by 34.31% to ¥10,297,554.56, attributed to the exit of a subsidiary from the reporting scope[9] - Total operating expenses of CNY 335,631,873.84, slightly down from CNY 344,749,889.04 in the previous year[24] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,976,492,969.42, reflecting a 2.96% increase from ¥2,890,879,605.71 at the end of the previous year[3] - Total liabilities amounted to CNY 854,295,630.57, up from CNY 768,713,644.87, indicating a rise of 11.1%[20] - The company’s total equity attributable to shareholders decreased slightly to CNY 2,076,076,269.13 from CNY 2,080,651,568.51, a decline of 0.2%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,989[11] - The largest shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., holds 23.43% of shares, totaling 247,426,064 shares[11] - The second-largest shareholder, Qiu Yu, holds 11.20% of shares, totaling 118,254,000 shares, which are currently frozen[11] - The total number of restricted shares at the beginning of the period was 211,111,111, with all being released during the period[14] - The total number of shareholders with voting rights restored for preferred shares is 0[11] Regulatory Approvals - The company received approval for the marketing application of Nicorandil, with a specification of 4kg/bag[15] - The company received approval for a supplementary application for Esomeprazole Sodium Injection, increasing the specification to 20mg[15] - The company obtained a drug registration certificate for Omeprazole Magnesium Enteric-coated Tablets (20mg)[15] - The company’s subsidiary received two medical device registration certificates from the National Medical Products Administration[16] Inventory and Cash Management - Cash and cash equivalents increased to CNY 926,826,531.80 from CNY 836,436,741.15, reflecting a growth of 10.8%[18] - The company reported a cash and cash equivalents balance of CNY 787,090,391.20 at the end of the quarter, down from CNY 852,320,224.62 at the end of the previous quarter[25] - Inventory increased to CNY 179,648,768.76 from CNY 170,996,939.13, representing a growth of 5.0%[18] - The company’s short-term borrowings rose to CNY 143,000,000.00 from CNY 113,500,000.00, an increase of 26.0%[19]